HomepageTWST • NASDAQ
add
Twist Bioscience Corp
Vorige slotkoers
$ 31,09
Dag-range
$ 30,58 - $ 31,79
Jaar-range
$ 23,30 - $ 55,33
Beurswaarde
1,83 mld. USD
Gem. volume
1,87 mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 99,01 mln. | 16,88% |
Bedrijfskosten | 80,77 mln. | 8,74% |
Netto inkomsten | -27,14 mln. | 21,69% |
Netto winstmarge | -27,41 | 33,00% |
Winst per aandeel | -0,45 | 23,73% |
EBITDA | -26,83 mln. | 16,12% |
Effectief belastingtarief | -0,96% | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 232,43 mln. | -15,91% |
Totale activa | 641,86 mln. | 4,48% |
Totale passiva | 168,90 mln. | 19,25% |
Totaal aandelenvermogen | 472,96 mln. | — |
Uitstaande aandelen | 61,15 mln. | — |
Koers-boekwaardeverhouding | 3,99 | — |
Rendement op activa | -11,64% | — |
Rendement op kapitaal | -13,19% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -27,14 mln. | 21,69% |
Operationele kasstroom | -11,81 mln. | 22,89% |
Kasstroom uit beleggingen | -12,40 mln. | -865,21% |
Kasstroom uit financiering | 5,57 mln. | 53,68% |
Nettomutatie in liquide middelen | -18,48 mln. | -43,20% |
Vrije kasstroom | -14,59 mln. | -124,74% |
Over
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Opgericht
2013
Website
Werknemers
979
